The Role and Regulation Factors of HIF-1A in Bone Regeneration

Authors

  • Yuanzhuo Shi

DOI:

https://doi.org/10.61173/3jnshf49

Keywords:

Hypoxia inducible factor-1A, bone regeneration, bone homeostasis, hypoxia

Abstract

As one of the most common diseases, bone injury has shown an upward trend during decades. Recent research have shown much more focus on regulating bone homeostasis and it details homeostasis and other pathways to accelerate initial recovery, which has a positive effect on both injuries and further treatment. This review discussed how HIF-1A dual-directionally regulates two important bone-related cells-osteoclasts and osteoblasts. and osteoblasts. It was found that HIF-1A could regulate cells through various pathways, including affecting their progenitor cells, metabolic pattern and HIF-1A downstream genes. This paper also discussed the regulation pathway of HIF-1A on both chemical and physical leading signals. The mechanical factors like substrate stiffness or shear stress have been studied that could regulate HIF-1A activity. Research has also found the effect of extracellular pH on HIF-1A activity through its two degradations PHD and VHL. This review summarized the HIF-1A effect on bone homeostasis with the regulatory pathways that could regulate its activity. This review also discusses the possible future research direction of how HIF-1A regulates its downstream genes and further influences hypoxia condition. It provides some valuable ideas for the development of this rapidly developing field.

References

[1] Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends in Biotechnology, 2012, 30(10): 546–554.

[2] Palumbo C, Ferretti M. The Osteocyte: From “Prisoner” to “Orchestrator.” Journal of Functional Morphology and Kinesiology, 2021, 6(1): 28.

[3] Zhou X, Cao H, Guo J, et al. Effects of BMSC-Derived EVs on Bone Metabolism. Pharmaceutics, 2022, 14(5): 1012.

[4] Liu M, Sun Y, Zhang Q. Emerging Role of Extracellular Vesicles in Bone Remodeling. Journal of Dental Research, 2018, 97(8): 859–868.

[5] Wan J-J, Yi J, Wang F-Y, et al. Expression and regulation of HIF-1a in hypoxic pulmonary hypertension: Focus on pathological mechanism and Pharmacological Treatment. Dean&Francis International Journal of Medical Sciences, 2024, 21(1): 45–60.

[6] Infantino V, Santarsiero A, Convertini P, et al. Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. International Journal of Molecular Sciences, 2021, 22(11): 5703.

[7] Mekhail K, Gunaratnam L, Bonicalzi M-E, et al. HIF activation by pH-dependent nucleolar sequestration of VHL. Nature Cell Biology, 2004, 6(7): 642–47.

[8] Lee K, Zhang H, Qian DZ, et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(42): 17910–17915.

[9] Lee J-W, Bae S-H, Jeong J-W, et al. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Experimental & Molecular Medicine, 2004, 36(1): 1–12.

[10] Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circulation Research, 2003, 93(11): 1074–1081.

[11] Kim J-M, Lin C, Stavre Z, et al. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells, 2020, 9(9): 2073.

[12] Veis DJ, O’Brien CA. Osteoclasts, Master Sculptors of Bone. Annual Review of Pathology, 2023, 18: 257–281.

[13] Lachowski D, Matellan C, Cortes E, et al. Self-Assembling Polypeptide Hydrogels as a Platform to Recapitulate the Tumor Microenvironment. Cancers, 2021, 13(13): 3286.

[14] Ponzetti M, Rucci N. Osteoblast Differentiation and Signaling: Established Concepts and Emerging Topics. International Journal of Molecular Sciences, 2021, 22(13): 6651.

[15] You J, Liu M, Li M, et al. The Role of HIF-1α in Bone Regeneration: A New Direction and Challenge in Bone Tissue Engineering. International Journal of Molecular Sciences, 2023, 24(9): 8029.

[16] Chen W, Wu P, Yu F, et al. HIF-1α Regulates Bone Homeostasis and Angiogenesis, Participating in the Occurrence of Bone Metabolic Diseases. Cells, 2022, 11(22): 3552.

[17] Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metabolic Bone Disease & Related Research, 1982, 4(1): 1–6.

[18] Tian Y, Shao Q, Tang Y, et al. HIF-1α regulates osteoclast activation and mediates osteogenesis during mandibular bone repair via CT-1. Oral Diseases, 2022, 28(2): 428–441.

[19] Chen K, Zhao J, Qiu M, et al. Osteocytic HIF-1α Pathway Manipulates Bone Micro-structure and Remodeling via Regulating Osteocyte Terminal Differentiation. Frontiers in Cell and Developmental Biology, 2021, 9: 721561.

[20] Wang P, Zhu P, Yu C, et al. The Proliferation and Stemness of Peripheral Blood-Derived Mesenchymal Stromal Cells Were Enhanced by Hypoxia. Frontiers in Endocrinology, 2022, 13: 873662.

[21] Yang M, Liu H, Wang Y, et al. Hypoxia reduces the osteogenic differentiation of peripheral blood mesenchymal stem cells by upregulating Notch-1 expression. Connective Tissue Research, 2019, 60(6): 583–96.

[22] Huang J, Deng F, Wang L, et al. Hypoxia induces osteogenesis-related activities and expression of core binding factor α1 in mesenchymal stem cells. The Tohoku Journal of Experimental Medicine, 2011, 224(1): 7–12.

[23] Regan JN, Lim J, Shi Y, et al. Up-regulation of glycolytic metabolism is required for HIF1α-driven bone formation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(23): 8673–8678.

[24] Dirckx N, Tower RJ, Mercken EM, et al. Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism. The Journal of Clinical Investigation, 2018, 128(3): 1087–1105.

[25] Shen X, Wan C, Ramaswamy G, et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. Journal of Orthopaedic Research, 2009, 27(10): 1298–1305.

[26] Komatsu DE, Bosch-Marce M, Semenza GL, et al. Enhanced bone regeneration associated with decreased apoptosis in mice with partial HIF-1alpha deficiency. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2007, 22(3): 366–374.

[27] Feng S, Bowden N, Fragiadaki M, et al. Mechanical Activation of Hypoxia-Inducible Factor 1α Drives Endothelial Dysfunction at Atheroprone Sites. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37(11): 2087–2101.

[28] Kim C-H, Cho Y-S, Chun Y-S, et al. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circulation Research, 2002, 90(2): E25-33.

[29] Cortes E, Lachowski D, Robinson B, et al. Tamoxifen mechanically reprograms the tumor microenvironment via HIF‐1A and reduces cancer cell survival. EMBO reports, John Wiley & Sons, Ltd 2019, 20(1): e46557.

Downloads

Published

2024-06-06